Utility and tolerability of diagnostic biomarker procedures in early-onset cognitive impairment

Takeaway

  • In a study of individuals with early-onset cognitive impairment, cerebral spinal fluid (CSF) biomarkers and amyloid-Positron Emission Tomography (PET) results increased neurologist confidence in diagnoses of Alzheimer’s disease (AD) and non-neurodegenerative disease (NND).

Why this matters

  • Amyloid-PET and biomarkers in CSF may be useful for AD diagnosis in those with early-onset cognitive impairment and are also tolerable to patients.